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Abstract
Fibroblast growth factor 19 (FGF19) is a hormone-like protein that regulates carbohydrate, lipid and bile acid metabolism. At
supra-physiological doses, FGF19 also increases hepatocyte proliferation and induces hepatocellular carcinogenesis in mice.
Much of FGF19 activity is attributed to the activation of the liver enriched FGF Receptor 4 (FGFR4), although FGF19 can
activate other FGFRs in vitro in the presence of the coreceptor bKlotho (KLB). In this report, we investigate the role of FGFR4
in mediating FGF19 activity by using Fgfr4 deficient mice as well as a variant of FGF19 protein (FGF19v) which is specifically
impaired in activating FGFR4. Our results demonstrate that FGFR4 activation mediates the induction of hepatocyte
proliferation and the suppression of bile acid biosynthesis by FGF19, but is not essential for FGF19 to improve glucose and
lipid metabolism in high fat diet fed mice as well as in leptin-deficient ob/ob mice. Thus, FGF19 acts through multiple
receptor pathways to elicit pleiotropic effects in regulating nutrient metabolism and cell proliferation.
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Introduction
FGF19 (fibroblast growth factor 19) and its murine ortholog
Fgf15 are the founding members of the endocrine FGF subfamily
that also includes FGF21 and FGF23 [1,2]. FGF19 and Fgf15
influence a variety of metabolic processes including glucose, lipid
and bile acid (BA) metabolism as well as gall bladder filling
[3,4,5,6]. Transgenic overexpression of FGF19 in mouse skeletal
muscle results in the accumulation of FGF19 in serum, and
reverses high fat diet (HFD)-induced weight gain and various
metabolic defects associated with obesity, including hepatic lipid
accumulation, insulin resistance, and increased serum lipid levels
[3,4]. Treatment of leptin deficient ob/ob mice or HFD-induced
obese mice with recombinant FGF19 causes an increase in
metabolic rate, resulting in weight loss, decreased hepatic
triglyceride content and a dramatic improvement in glucose
utilization and insulin sensitivity [3]. Very similar metabolic effects
have more recently been described for FGF21, the most closely
related member of the FGF superfamily to FGF19 (and murine
Fgf15), suggesting that FGF19 and FGF21 may act through a
common receptor pathway [7,8,9].
In addition to the effects on lipid and glucose metabolism,
FGF19/Fgf15 has also been implicated in the regulation of
hepatic BA metabolism and hepatocyte proliferation. FGF19/
Fgf15 expression in the intestine is transcriptionally regulated by
the nuclear BA receptor Farnesoid X Receptor (FXR) [5,10] and
is induced in the post-prandial state in humans, when BA levels
rise in the lumen of the distal small intestine [11]. Circulating
FGF19/Fgf15 in turn induces the hepatic expression of atypical
nuclear receptor Small Heterodimeric Partner (SHP) to suppress
expression of Cyp7a1 and Cyp8b1 encoding cholesterol 7a-
hydroxylase and Sterol 12 alpha-hydroxylase respectively, two
key enzymes for hepatic BA synthesis [3,5,10,12,13]. Accord-
ingly, Fgf15 deficient mice exhibit an increase in fecal BA
excretion [5], and conversely, hepatic overexpression of Fgf15
reduces fecal BA excretion [14]. Recombinant FGF19 also has
the ability to induce hepatocyte proliferation in the liver as
measured by BrdU incorporation into DNA [15,16,17]. Indeed,
FGF19 expressing transgenic mice exhibit increased hepatic
BrdU incorporation and elevated expression of a-fetoprotein
(AFP) mRNA, a marker for hepatocyte proliferation, as early as
2 months of age, and go on to spontaneously develop
hepatocellular carcinomas [15].
FGF19/Fgf15 is believed to act by activating FGF receptor
(FGFR) homodimers complexed with a membrane bound protein
bKlotho (KLB) [13,18,19]. Humans and mice possess four
conserved FGFR genes, of which FGFR1-3, but not FGFR4,
are alternatively spliced in the extracellular ligand binding domain
to yield two principal isoforms, b and c, each exhibiting distinct
ligand binding specificity [2]. In the presence of KLB, FGF19 can
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isoforms, FGFR4 appears to mediate many, if not all, FGF19
activities. Fgfr4 deficient mice exhibit elevated Cyp7a1 mRNA
expression, BA excretion and pool size [20] and fail to suppress
Cyp7a1 expression upon injection of adenovirus expressing Fgf15
[5]. Furthermore, our unpublished results show that FGF19
transgenic mice do not develop hepatocellular carcinoma in Fgfr4
deficient background (French DM, in preparation). Whether other
FGFRs mediate FGF19 activity in vivo is currently not clear. In
this report, we investigate the requirement for FGFR4 in
mediating FGF19 activity by using Fgfr4 deficient mice as well
as a protein variant of FGF19, which is specifically impaired in its
ability to activate FGFR4. Our results indicate that FGFR4
activation is essential for some of the activities of FGF19, but is
dispensable for the beneficial effects of FGF19 on glucose and lipid
metabolism, demonstrating the existence of an FGFR4-indepen-
dent pathway of FGF19 action.
Results
FGFR4 is required for regulation of serum bile acids, but
not for improvement of glucose tolerance, by
recombinant FGF19
In order to determine which of the metabolic effects elicited by
FGF19 are mediated by FGFR4, we treated HFD-fed WT or
Fgfr4 KO mice with recombinant FGF19 or vehicle control and
studied metabolic phenotypes and gene expression. To achieve
sustained exposure to FGF19, mice were implanted with osmotic
pumps to continuously infuse FGF19 at 1 ng/hr. This achieved an
average FGF19 serum concentration of 26 ng/ml, as determined
by ELISA, about 50- to 250-fold higher than circulating FGF19
concentrations in humans [11]. On day 6, a glucose tolerance test
was conducted after overnight fasting. FGF19 infusion improved
glucose tolerance to a similar extent both in WT and Fgfr4 KO
mice (Fig. 1A), indicating that FGFR4 is dispensable for the
improvement in glucose tolerance in HFD-fed mice. Continuous
infusion of FGF19 did not induce significant weight loss, thus the
improved glucose tolerance was independent of body weight. By
day 7, FGF19 reduced liver weight and serum insulin and
increased ketone body (b-hydroxybutyrate: BHB) formation in
both WT and Fgfr4 KO mice (Fig. 1B). The mock-treated Fgfr4
KO mice exhibited reduced lactate and triglyceride levels
compared to WT mice, and FGF19 reduced these parameters in
WT but not Fgfr4 KO mice (Fig. 1B).
To evaluate changes in systemic BA regulation, serum BA
composition was determined by liquid chromatography-mass
spectrometry (Fig. 1C). Although serum BA composition is
influenced by a number of factors including hepatic synthesis
and transport in the liver, kidney and intestine [21,22], our finding
is consistent with a shift of BA synthesis from the neutral to the
alternative (acidic) pathway, bypassing FGF19-suppressed Cyp7a1
and proceeding though Cyp7b1 (Fig. 1D). FGF19 infusion in WT
mice reduced free and taurine conjugated cholic acid (CA) and the
CA-derived secondary bile acid deoxycholic acid, while having
minimal effect on chenodeoxycholic acid (CDCA) metabolites,
muricholic acids (MCA). Correspondingly, loss of Fgfr4 increased
basal levels of CA and its metabolites while reducing MCA
(hydroxylated metabolites of CDCA), indicating that FGFR4 is not
only important as a regulator of bile acid synthesis, but is also a
determinant of the ratio of CA to CDCA production. To
determine the role of FGFR4 in regulation of hepatic gene
expression, we examined a range of hepatic mRNAs by qPCR
(Fig. 1D). FGF19 infusion induced expression of cell proliferation
markers such as Egr-1, c-Fos, and AFP, and suppressed expression
of Cyp7a1 in WT but not in Fgfr4 KO mice. In contrast, FGF19
suppressed Cyp8b1 and glucokinase (GK) in both WT and Fgfr4
KO mice, while basal expression of Cyp8b1 and Cyp27a1 levels
were much higher in Fgfr4 KO compared to WT mice. The
higher basal expression of the Cyp genes is most likely due to loss
of suppression by endogenous Fgf15 protein. Although an increase
in basal expression was also observed for Egr-1, this was not
reproduced in other experiments (see below). Cyp8b1 is obligatory
for the synthesis of cholic, but not CDCA [23], thus the observed
changes in Cyp8b1 expression contribute to the altered balance
between CA and CDCA metabolites (muricholic acids) in Fgfr4
KO mice (Fig. 1C and D). Taken together, our findings reveal that
FGFR4 is a pivotal regulator of BA synthesis and impacts
hepatocyte proliferation, but is not required for the regulation of
glucose utilization, insulin sensitivity, and ketone body production
by FGF19.
Identification of FGF19 variants with a specific reduction
in FGFR4 activation
Based upon the results described above, we hypothesized that if
we could generate FGF19 variants with specifically reduced
FGFR4 activity, such molecules would retain beneficial metabolic
effects while losing FGFR4-dependent actions such as the
induction of hepatocyte proliferation and altered BA homeostasis.
In order to quantitatively evaluate specific activation of FGFRs by
FGF19, an FGF-responsive GAL-Elk1 luciferase reporter assay
was introduced into rat L6 cells [24]. In this assay, effective
binding of a ligand to FGFR results in activation of an endogenous
MAP kinase pathway, leading to subsequent activation of a
chimeric transcriptional activator comprising of an Elk-1 activa-
tion domain and a GAL4 DNA-binding domain. L6 cells lack
functional FGFR or KLB and are only responsive to FGF19 or
FGF21 when cotransfected with cognate receptors [18]. Using this
assay, we observed that FGF19 and FGF21 activated FGFR1c, 2c
and 3c in the presence of KLB, with similar potency and efficacy
(Fig. 2A and S1). In contrast, FGF19, but not FGF21, efficiently
activated FGFR4, even in the presence of KLB (Fig. 2A). To map
the signals required for FGFR4 activation, we generated a number
of chimeric constructs between FGF19 and FGF21 using
conserved residues to form junctions (Fig. 2B). Constructs were
expressed in HEK293 cells and the culture supernatants
containing secreted chimeric FGF proteins were tested for
activation of FGFR1c and/or FGFR4 in KLB-expressing L6 cells
using the GAL-Elk1 reporter assay. Based on the activity of
FGFR1c and FGFR4, the chimeric constructs were classified into
4 classes: high FGFR1c and FGFR4 activity (Class I, FGF19-like);
high FGFR1c activity and low, but detectable FGFR4 activity
(Class II); high FGFR1c activity without detectable FGFR4
activity (Class III, FGF21-like) (Fig. 2C and S2) and very low or
undetectable FGFR1c and FGFR4 activity due to poor expression
(Class IV) (not shown). This mapping indicated that the N-
terminal 39 amino acids of FGF19 are sufficient to confer some
FGFR4 activity when transferred to FGF21. In addition, the N-
terminal 24 amino acids and the C-terminal 49 amino acids of
FGF19 are necessary for full FGFR4 activity, but are not sufficient
to confer FGFR4 activity when transferred to FGF21. Thus
multiple signals at both the N-terminus and C-terminus of FGF19
contribute to FGFR4 activation.
One chimeric construct classified as a class II molecule,
consisting of amino acids 1-20 of FGF21 and 25-194 of FGF19
(. 90% identical to FGF19), was selected for large scale synthesis
in CHO cells and this variant is referred to as ‘‘FGF19v’’. When
compared with FGF19 using the luciferase reporter assay, FGF19v
protein exhibited a similar dose-dependent activity to FGF19 in
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FGF19v activity was significantly diminished in L6 cells cotrans-
fected with a combination of FGFR4 and KLB (Fig. 2D). FGF19
activated FGFR4 even in the absence of KLB coexpression in a
similar luciferase assay (Fig. 2D), and as previously shown [25,26],
exhibited dose-dependent binding activity to FGFR4 (Fig. 2E and
F). However, these activities were largely abrogated for FGF19v
(Fig. 2D, E and F).
Figure 1. Fgfr4 is required for BA regulation but not for improvement of glucose tolerance by FGF19. (A) 12 to 15 week old Fgfr4 WT
and KO mice on high fat diet for 6 weeks were implanted with an osmotic pump to infuse FGF19 at 1 ng/hr (day 0). On day 6, overnight fasted mice
were subjected to glucose tolerance test with i.p. injection of glucose at 1 g/kg. *p,0.05. **p,0.01. p value for area under the curve (AUC) was
p,0.02 (WT) and p,0.005 (KO). N=6,8. Note that fasting blood glucose levels were significantly higher in PBS-treated Fgfr4 KO mice compared
with WT mice (#p,0.01). (B) Metabolic parameters at euthanasia on day 7. Mice were euthanized and serum prepared after 3 hr fast. N=6,8. (C)
Serum BA composition analysis. Only major BA species are shown. CA: cholic acid, DCA: deoxycholic acid, MCA: muricholic acid, T-:taurine-
conjugated.ˆ: undetected. (D) Hepatic gene expression determined by real-time qPCR. N=6,8. p values for (B), (C), and (D): ,0.05, **,0.005 (PBS vs
FGF19), #,0.05, ##,0.005 (WT vs Fgfr4KO).
doi:10.1371/journal.pone.0017868.g001
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PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e17868Figure 2. Identification of FGF19 variants with reduced FGFR4 activity. (A) GAL-Elk1 luciferase assay in rat L6 cells. L6 cells were
cotransfected with expression vectors for KLB and the indicated FGFR together with GAL-Elk1, SV40-renilla Luciferase, and Gal-responsive firefly
luciferase reporter. Transfected cells were incubated with media containing increasing concentrations of FGF19 (#) or FGF21(m) for 6 hours before
luciferase assays. Transcriptional activation was assessed by the relative firefly luciferase activity normalized by renilla luciferase activity and expressed
as relative luciferase unit (RLU). (B) Drawings (to scale) of FGF19 (top), FGF21 (bottom), and various chimeric proteins with amino acid composition at
left. Based on the results of repeated GAL-Elk1 assays such as shown in (C), each chimera was classified into class (I), (II) or (III) as indicated at right (see
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Activity of FGF19v was further tested in vivo in comparison
with FGF19 and FGF21 by intravenously injection into overnight
fasted FVB mice. Livers were harvested at 4 hours post injection
and hepatic mRNA expression was determined by qPCR. Genes
that were acutely induced by FGF19 but not by FGF21, such as
Egr-1 and c-Fos, were not efficiently induced by FGF19v,
consistent with the reduced FGFR4 activity of FGF19v (Fig. 3A).
FGF19v had similar activity to FGF19 or FGF21 on genes co-
regulated by FGF19 and FGF21, such as GK. Using Fgfr4 KO
mice, we confirmed that FGFR4 contributes to the regulation of
Egr-1 and c-Fos, but not GK, by FGF19 (Fig. 3B). Unexpectedly,
FGF21 (as well as FGF19 and FGF19v) altered expression of SHP
and Cyp7a1 (Fig. 3A), which were proposed to be major targets for
FGFR4-dependent regulation by FGF19 [5]. Alterations in SHP
and Cyp7a1 by FGF19 and FGF21 were observed even in Fgfr4
KO mice, indicating that with this acute treatment, both
endocrine FGFs can modulate expression of these genes through
an FGFR4-independent pathway (Fig. 3B).
It has been previously proposed that FGFR4 mediates the
induction of hepatocyte proliferation by FGF19 [16] (French,
D.M., in preparation). Consistent with this concept, FGF19
increased anchorage-independent proliferation of HepG2 cells in
soft agar, and this effect was much less apparent for FGF19v or
FGF21 proteins (Fig. 3C). To see whether FGF19v also exhibited
reduced ability to induce hepatocyte proliferation in vivo, mice
were infused with FGF19, FGF19v (1 ng/h) or vehicle control by
osmotic mini-pump. In addition, 1 mg/kg/day of FGF protein
was injected intraperitoneally daily for 7 days to the same mice to
achieve high peak exposures. To capture intermittent proliferative
events, BrdU solution (30 mg/kg) was injected twice daily for a
total of 13 injections. Hepatocyte proliferation was determined by
measuring BrdU positive hepatocytes in liver harvested on day 7.
As previously reported, FGF19 treatment resulted in a dramatic
increase in BrdU incorporation; however, this response was
significantly blunted for FGF19v (Fig. 3D and E). Hepatic mRNA
for Egr-1, c-Fos, and the hepatocyte proliferation marker AFP
were all dramatically induced by FGF19 and these inductions were
largely absent for FGF19v, while regulation of GK, Cyp7a1 and
Cyp8b1 did not differ between FGF19 and FGF19v (Fig. 3F).
FGFR4 is not required for amelioration of hyperglycemia
in ob/ob mice by FGF19
The in vitro and in vivo results described above raised the
question as to whether FGF19v, a variant of FGF19 with reduced
FGFR4 activity and proliferative potential, could improve
hyperglycemia in diabetic animals similar to FGF21. FGF21,
FGF19v (1ng/hr) or vehicle control was continuously infused
subcutaneously into ob/ob mice using osmotic mini-pumps. While
infusion did not significantly affect body weight (Fig. 4A), both
FGF21 and FGF19v dramatically reduced blood glucose levels in
both random fed and fasted mice (Fig. 4A and B), reduced
circulating free fatty acid levels (Fig. 4C), and improved glucose
tolerance (Fig. 4D). In addition, gross liver weight was significantly
reduced for both FGF21 and FGF19v treated mice (Fig. 4E).
Presumably reflecting a low level FGFR4 activation by FGF19v
that we observed in vitro (Fig. 2) and in vivo in lean FVB mice
(Fig. 3), Cyp7a1 gene expression was modestly, but significantly
suppressed by FGF19v, but not by FGF21 (Fig. 4F). However, no
significant change in hepatic expression of AFP mRNA was
observed in either FGF-treated groups (Fig. 4F).
The mechanism by which FGF21 and FGF19 ameliorate
hyperglycemia in diabetic animals is not well understood. Since
FGF21 and FGF19v show very similar anti-diabetic effects in ob/
ob mice, we hypothesize that commonly regulated pathways may
contribute to their anti-diabetic effects. We identified a number of
genes exhibiting commonly altered expression in ob/ob mice
treated with FGF21 and FGF19v. In the liver, both proteins
induced IGFBP2 (a recently demonstrated anti-diabetic protein)
[27], and suppressed stearoyl-Coenzyme A desaturase 1 (SCD-1; a
lipogenic gene) and Cyp8b1 (the determinant of the balance
between CA and CDCA production) [23]. In addition, they both
induced UCP-1 (adaptive thermogenesis), SCD-1 and Medium-
Chain Acyl-CoA Dehydrogenase (MCAD; mitochondrial fatty
acid oxidation) in brown adipose tissue, and SREBP-1c (lipogenic
transcription factor) in white adipose tissue (Fig. 4F). Thus, actions
in multiple tissues could mediate the anti-diabetic effects of FGF21
and FGF19v acting through a FGFR4 independent mechanism.
Discussion
Although FGF19 has been shown to activate multiple FGFRs in
the presence of the coreceptor KLB in vitro, contribution of each
FGFR to the in vivo activity of FGF19 has been poorly defined.
Our findings in Fgfr4 KO mice as well as using a FGF19 variant
protein with reduced FGFR4 activity have delineated pathways
downstream of FGF19. We have shown that FGFR4 is required
for regulation of BA biosynthesis and hepatocyte proliferation as
previously proposed [5,16]. However, an important additional
finding of this work is that FGF19 is also a key qualitative regulator
of systemic BA composition. By examining individual serum BA
we have demonstrated that recombinant FGF19, acting through
Fgfr4, suppresses Cyp7a1 causing bile acid synthesis to proceed by
the Cyp7a1-independant alternate (acidic) pathway (Fig. 5A),
leading to the production of CDCA at the expense of CA. We also
found that Cyp8b1 expression increased several-fold in Fgfr4
knockout mice and that FGF19 treatment suppresses Cyp8b1, an
obligatory enzymatic step for CA synthesis (Fig. 5A). It is therefore
apparent that FGFR4 is important in determining the ratio of
CDCA to CA production, through the negative regulation of both
Cyp7a1 and Cyp8b1. FGFR4 activation shifts BA production
towards CDCA, while its abrogation leads to CA formation. In
addition, FGF19 increased hepatic AFP expression in a Fgfr4
dependent manner, consistent with previous reports [16].
Intriguingly, we found that both FGF19 and FGF21 acutely
reduce hepatic expression of Cyp7a1 even in Fgfr4 KO mice
text). Chimeras which did not exhibit an equivalent FGFR1c activity to FGF21 or FGF19 when conditioned medium was used were not shown here. (C)
Representative results of GAL-Elk-1 assay for chimeras shown in (B). L6 cells were cotransfected with expression vectors for KLB and/or FGFR as
indicated at right. Each FGF construct was expressed in transiently transfected 293 cells and the conditioned medium was used in the assay. The
results are shown as a fold induction over control media conditioned with mock transfected cells. (D) Similar to (A). Purified FGF19 (#) and FGF19v
(.), (the construct #4 in (B) and (C)), were tested for FGFR activation in the presence or absence of KLB coexpression as indicated. (E) Solid phase
binding assay of FGF19 and FGF19v to FGFR4 fused to Fc fragment was tested as described in the method section. Schematic diagram for the
experiments is shown at right. Bold Y indicates antibody against FGF19 (black) or Fc fragment (gray). HRP: horseradish peroxidase. (F) A control ELISA
experiment to show that anti-FGF19 antibody used in (E) recognize FGF19 and FGF19v at indistinguishable affinity. Schematic diagram for the
experiments is shown at right.
doi:10.1371/journal.pone.0017868.g002
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continuous infusion of FGF19 repressed Cyp7a1 expression only
in WT, but not in Fgfr4 KO mice (Fig. 1D), and continuous
infusion of FGF21 did not repress Cyp7a1 expression in HFD-fed
mice [7] or in ob/ob mice (Fig. 4F). In contrast, Fgfr4-
independent repression of Cyp8b mRNA expression by FGF19
or FGF21 was consistently observed even in chronic conditions [7]
(Fig. 1D and 4F). One candidate FGFR that might mediate the
Fgfr4-independent regulation of Cyp7a and Cyp8b is FGFR2c,
which is expressed in the liver [28] and can interact with KLB to
form a receptor for both FGF19 and FGF21 [18]. Further work is
required to elucidate the biological significance of this Fgfr4-
independent Cyp regulation.
Fgfr4 has also been implicated in the regulation of lipid
metabolism and glucose tolerance and may indeed mediate
regulation of fat metabolism by endogenously produced Fgf15
protein [29]. However, our results indicate that Fgfr4 is unlikely to
be important for the regulation of glucose and lipid metabolism by
FGF19 at a pharmacological dose. FGF19 improves glucose
tolerance in HFD-fed Fgfr4 KO mice (Fig. 1) and FGF19v, a
protein specifically impaired of FGFR4 binding and activation,
ameliorates hyperglycemia in ob/ob mice (Fig. 2-4). This work
compliments previous studies using a FGF19 variant that selectively
activatesFGFR4andinduceshepatocyteproliferationtosuggestthe
role of FGFR4 for induction of hepatocyte proliferation but not for
improvement in glucose metabolism by FGF19 [16,30]. The
activity of FGF19 to improve insulin resistance and hyperglycemia
in obese and diabetic mice is shared by a related endocrine FGF,
FGF21 [7,8,9]. In addition to the effects in insulin resistance and
glucose metabolism, FGF19 increases serum BHB levels even in
Fgfr4 KO mice (Fig. 1), like FGF21 [31]. Both FGF19 and FGF21
can bind and activate FGFR1c, FGFR2c, and FGFR3c in the
presence of KLB [30,32,33]. Thus FGFR1c, FGFR2c, or FGFR3c,
in cooperation with KLB, are likely to mediate the common
metabolic effects of FGF19 and FGF21 (Fig. 5B).
Previously, therapeutic potential for FGF19 in the treatment of
obesity and diabetes has been proposed [3,4]; however, its
promotion of hepatocyte proliferation and carcinogenic potential
challenges the development of FGF19 for chronic use [15]. With
the identification of FGFR4 as the receptor mediating the
induction of hepatocyte proliferation but not the improvement
in glucose tolerance, it was predicted that FGF19-like molecules
with reduced FGFR4 activity should provide metabolic benefits
without causing unwanted side effects. Indeed, we have identified
a chimeric FGF19v protein that fits these criteria; it ameliorates
hyperglycemia and hyperinsulinemia without a detectable increase
in hepatic AFP expression in ob/ob mice. When lean and tumor-
prone FVB mice were challenged with a supra-therapeutic dose by
combination of continuous infusion and daily injection, FGF19v
induced only a two-fold increase in hepatic BrdU incorporation
compared with vehicle-treated mice, whereas FGF19 induced on
average .9 fold increase. While it is not clear how significant this
residual level of FGFR4 activity of FGF19v molecule would be in
the therapeutic setting, in particular considering humans have
endogenous FGF19 protein, further fine mapping of amino acid
residues that are important for FGFR4 interaction should help to
identify FGF19 variants without residual FGFR4 activity, thus
with no proliferative actions. Such proteins would have therapeu-
tic potential for the treatment of insulin resistance, type 2 diabetes,
and the broader metabolic syndrome [8].
Each FGF family protein consists of the structurally conserved
central globular domain, and the flanking N-terminal and C-
terminal segments that are structurally flexible and are divergent
in primary sequence. In X-ray crystal structures of multiple FGF/
FGFR complexes, the N-terminal segment of the FGF molecule
makes specific contact with the FGFR and is believed to play an
important role determining the specificity of the FGF-FGFR
interaction [34]. Through our efforts to identify specific regions
within FGF19 that are important for FGFR4 activation, we found
that changing the entire N-terminal segment (amino acid 1–24) of
FGF19 to that of FGF21 substantially removes FGFR4 activations
without impairing its ability to activate FGFR1 (in the presence of
KLB) (Fig. 2). Conversely, changing N-terminal 34 amino acid of
FGF21 to the corresponding sequence of FGF19 confers activation
of FGFR4. Thus, determinants of receptor specificity reside within
the flexible N-terminal segments of FGF19, although other regions
within FGF19 are essential for maximum activation of FGFR4.
While this manuscript was in preparation, Wu et al. reported an
identification of a FGF19 variant with a dramatically reduced
ability to activate FGFR4, but that was only modestly compro-
mised for FGFR1c activation and retained the ability to acutely
reduce blood glucose levels in ob/ob mice [17]. In this variant
called FGF19-4, five amino acids in the N-terminal segment
(amino acid 16–20) and 8 amino acids at the N-terminal end of the
globular domain (amino acid 28–35) were replaced with the
corresponding residues in FGF21, supporting the importance of
the N-terminal segments in determination of FGFR-binding
specificity. Our systematic and quantitative approach provides
further insight to the determinants of functional specificity in the
FGF19/FGFR interaction.
In conclusion, our study demonstrates that FGFR4 is not
required for beneficial pharmacological activity of FGF19, and that
an engineered FGF19 variant mimicking the specificity of FGF21
could successfully be generated. Given the pleiotropic activities of
FGF19 and FGF21 onmultiple receptors(i.e., FGFR1c, 2c,and 3c),
further exploration into altering receptor specificity of FGF19 or
FGF21 to achieve specific activation of a particular FGFR may
provide a safer and more predictable approach to exploit endocrine
FGF pathways and provide new therapeutic options for the
epidemic of obesity associated-disorders such as type 2 diabetes,
nonalcoholic fatty liver disease and other manifestations of insulin
resistance and the metabolic syndrome.
Figure 3. Biological activities of FGF19v in chow-fed lean mice. (A) An acute gene expression study. Overnight fasted FVB mice (N=5–6) were
injected via tail vein with indicated FGF protein at 1 mg/kg or PBS control. At 4 hours post-injection, hepatic mRNA was prepared from each mouse
and subjected to real-time qPCR analysis for the indicated genes. p values: *,0.05, **,0.01, ***,0.001 (vs PBS) (B) A similar acute gene expression
study. Overnight fasted WT or FGFR4 KO mice (N=5–7) were i.p. injected with indicated FGF protein at 1 mg/kg or PBS control. At 4 hours post-
injection, hepatic mRNA was prepared from each mouse and subjected to real-time qPCR analysis for the indicated genes. p values: *,0.05, **,0.01,
***,0.001 (vs PBS) (C) Anchorage independent cell growth assay. Proliferation of HepG2 cells in soft agar was estimated based on conversion of
Resazurin (Alamer Blue), a non-fluorescent indicator dye, to resorufin. (D) Hepatic BrdU incorporation in FGF treated mice. FVB mice were implanted
with an osmotic pump to continuously infuse indicated FGF protein at 1 ng/hr (,0.8 mg/kg/day) (day 0). The mice also received daily injection of
1 mg/kg/day FGF protein (q.d.) and 30 mg/kg/day BrdU (b.i.d.) starting day 1. On day7, livers were dissected out and subjected to anti-BrdU staining.
The results are shown as a fold induction over mock treated animals for the number of BrdU positive hepatocytes per area anlyzed. p values for (C)
and (D): N=6, *p,0.01, ***p,5E25 (vs PBS), ##p,0.0002 (vs FGF19) (E) Representative images for (C). (F) Hepatic gene expression profile in mice
used for (D) and (E). N=6. *p,0.05, **p,0.005, ***p,0.001 (vs PBS), #p,0.05, ##p,0.005 (FGF19 vs FGF19v).
doi:10.1371/journal.pone.0017868.g003
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Research ethics
The study protocols for all animal experiments were approved
by the Genentech Institutional Animal Care and Use Committee
(IACUC). The approval IDs for this study are: #08-1943, #08-
2004, #08-2004A, #08-2004B, #08-2004C, #08-2136, #08-
2136F, #09-1001, #09-1066, #10-1818.
Expression of recombinant FGF protein
Unless otherwise noted, recombinant human FGF21, FGF19
and variants produced in transiently transfected CHO cell and
purified to homogeneity in PBS were used for experiments. For
some experiments, E. coli derived FGF21 (2539-FG/CF, R&D
systems) was used. All the purified proteins were tested for
activity by cell based GAL-Elk1 assays prior to use in for other
assays. For experiments in Fig. 2B, 2C, and S2, FGF proteins
were expressed in transiently transfected HEK293 cells and fresh
conditioned serum-free medium was used for assays without
purification.
Amino acid sequences of FGF19, FGF21 and chimeras
All the constructs also possessed a signal sequence at the N-
terminal end (cleaved upon secretion) and the flag tag
Figure 4. FGF19v and FGF21 exhibit similar metabolic effects and ameliorate hyperglycemia in ob/ob mice. 11-week-old ob/ob mice
were subcutaneously implanted with an osmotic pump to infuse 1 ng/hr FGF protein (0.4 mg/kg/day) or PBS control (N=7). (A) Changes in body
weight and random fed blood glucose level. The osmotic pump was implanted on day 0. (B) Blood glucose levels at random fed condition and after
overnight fast. (C) Serum non-esterified fatty acids (NEFA) levels on day 8. (D) Glucose tolerance test conducted on day 6. Mice were overnight fasted
and i.p. injected with 1 g/kg glucose at t=0. (E) Organ/body weight ratio on day 8. (F) qPCR gene expression profiles on indicated organs. p values:
*,0.05, **,0.005, ***,0.0005 (vs PBS control), ##p,0.005 (FGF21 vs FGF19v).
doi:10.1371/journal.pone.0017868.g004
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from FGF21 are shown in bold.
1 (hFGF19): RPLAFSDAGPHVHYGWGDPIRLRHLYTSGP-
HGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRTVAIK-
GVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDGYN-
VYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMV-
PEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRS-
PSFEK
2: RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSC-
FLRIRADGVVDCARGQSAHSLLEIKALKPGTVAIKGVHS-
VRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDGYNVYR-
SEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEE-
PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK
3: HPIPDSSPHVHYGWGDPIRLRHLYTSGPHGLSSCFL-
RIRADGVVDCARGQSAHSLLEIKAVALRTVAIKGVHSVR-
YLCMGADGKMQGLLQYSEEDCAFEEEIRPDGYNVYRSE-
KHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPE-
DLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK
4 (hFGF19v): HPIPDSSPLLQFGGQVRQRYLYTSGP-
HGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRTVA-
IKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEEEIRPD-
GYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPM-
LPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEA-
VRSPSFEK
5: HPIPDSSPLLQFGGQVRQRYLYTDDPHGLSSCFLR-
IRADGVVDCARGQSAHSLLEIKAVALRTVAIKGVHSVRY-
LCMGADGKMQGLLQYSEEDCAFEEEIRPDGYNVYRSEK-
HRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPED-
LRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK
6: HPIPDSSPLLQFGGQVRQRYLYTDDAQLSSCFLRI-
RADGVVDCARGQSAHSLLEIKAVALRTVAIKGVHSVRYL-
CMGADGKMQGLLQYSEEDCAFEEEIRPDGYNVYRSEKH-
RLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL-
RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK
7: HPIPDSSPLLQFGGQVRQRYLYTDDAQQTSCFLRI-
RADGVVDCARGQSAHSLLEIKAVALRTVAIKGVHSVRYL-
CMGADGKMQGLLQYSEEDCAFEEEIRPDGYNVYRSEKH-
RLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL-
RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK
8: RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSC-
FLRIRADGVVDCARGQSAHSLLEIKAVALRTVAIKGVHS-
VRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDGYNVY-
RSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPLPGLPP-
ALPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYAS
9: RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSS-
CFLRIRADGVVDCARGQSAHSLLEIKAVALRTVAIKGVK-
TSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYNVY-
QSEAHGLPLHLPGNKSPHRDPAPRGPARFLPLPGLPPA-
LPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYAS
10: RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSS-
CFLRIRADGVVDCARGQSAHSLLQLKALKPGVIQILGV-
KTSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYN-
VYQSEAHGLPLHLPGNKSPHRDPAPRGPARFLPLPGL-
PPALPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYAS
11: RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSS-
CFLRIRADGVVDCARGQSPESLLQLKALKPGVIQILGVK-
TSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYNVY-
QSEAHGLPLHLPGNKSPHRDPAPRGPARFLPLPGLPPA-
LPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYAS
12: RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSS-
CFLRIRADGTVGGAADQSPESLLQLKALKPGVIQILGVK-
TSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYNVY-
QSEAHGLPLHLPGNKSPHRDPAPRGPARFLPLPGLPPA-
LPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYAS
13: RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSS-
CFLRIREDGTVGGAADQSPESLLQLKALKPGVIQILGVK-
TSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYNVY-
QSEAHGLPLHLPGNKSPHRDPAPRGPARFLPLPGLPPA-
LPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYAS
14: RPLAFSDAGPHVHYGWGDPIRLRHLYTDDAQQTE-
AHLEIREDGTVGGAADQSPESLLQLKALKPGVIQILGV-
KTSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYNV-
YQSEAHGLPLHLPGNKSPHRDPAPRGPARFLPLPGLPP-
ALPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYAS
15: RPLAFSDAGPLLQFGGQVRQRYLYTDDAQQTEA-
HLEIREDGTVGGAADQSPESLLQLKALKPGVIQILGVK-
TSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYNVY-
QSEAHGLPLHLPGNKSPHRDPAPRGPARFLPLPGLPPA-
LPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYAS
16: HPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHL-
EIREDGTVGGAADQSPESLLQLKALKPGVIQILGVKTSR-
FLCQRPDGALYGSLHFDPEACSFRELLLEDGYNVYQSE-
Figure 5. Models for metabolic pathways regulated by FGF19, FGF19v and FGF21. (A) Schematic diagram showing hepatic biosynthetic
pathways that convert cholesterol into bile acids. The classical (neutral) pathway (center) is initiated by Cyp7A1, whereas the alternate (acidic)
pathway (right) is initiated by Cyp27a1 and Cyp7b1. According to our model, FGF19 suppresses the classical pathway through transcriptional
regulation of Cyp7a1 and Cyp8b1, shifting BA synthesis towards production of CDCA or its derivatives. (B) Distinct FGFR/KLB receptor complexes
mediate various biological activities of FGF19, FGF19v, and FGF21. In addition to the model depicted, FGF21 and FGF19 can also suppress Cyp7a1
expression acutely in FGFR4-independent manner (Fig. 3).
doi:10.1371/journal.pone.0017868.g005
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DLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK
17 (hFGF21): HPIPDSSPLLQFGGQVRQRYLYTDDA-
QQTEAHLEIREDGTVGGAADQSPESLLQLKALKPGVIQ-
ILGVKTSRFLCQRPDGALYGSLHFDPEACSFRELLLEDG-
YNVYQSEAHGLPLHLPGNKSPHRDPAPRGPARFLPLPG-
LPPALPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYAS
Luciferase assay
All the cells were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) at 37uC under 5% CO2. Rat L6 myoblasts in a 96-well plate
were transiently-transfected with expression vectors encoding
Renilla luciferase (pRL-SV40, Promega), human KLB, appropri-
ate human FGFR, GAL4-Elk-1 transcriptional activator (pFA2-
Elk1, Stratagene), and firefly luciferase reporter driven GAL4
binding sites (pFR-luc, Stratagene), using FuGENE HD Trans-
fection Reagent (Roche Applied Science). On the next day, the
transfected cells were cultured for an additional 6–8 hours in
serum free media containing 25 mg/L porcine heparin (Sigma)
and FGF protein at a various concentration. The cells were then
lysed with PLB reagent (Promega) and luciferase activity in each
well was determined using Dual-Glo Luciferase Assay System
(Promega) and EnVision Multilabel Reader (PerkinElmer). Firefly
luciferase activity was normalized to the co-expressed Renilla
luciferase activity, and is shown as an average and standard error
of the mean of the three replicas.
Anchorage independent cell proliferation assay
A 96-well-plate was filled with 50 mL/well of 0.5% molten
agarose in growth media. After the base agarose had solidified,
about 670 HepG2 cells suspended in 50 mL top molten agarose
solution (0.35% agarose in growth media) were added to the base
agar in each well, and allowed to solidify. Following solidification,
20 mL of growth medium containing an appropriate amount of
FGF protein was added to each well on designated day 0. On each
of the subsequent days 2, 4, 6 and 8, a further 20 mL of growth
medium with an appropriate amount of FGF protein was added to
each well. A subset of the sample wells was also treated with
protein synthesis inhibitor Geneticin (Invitrogen) to provide a
background fluorescence signal. On day 9, 10 mL AlamarBlue
reagent (Invitrogen) was added to each sample well and the plate
was further incubated for 5 hrs. The resulting fluorescent intensity
was measured using EnVision Multilabel Reader (PerkinElmer)
and used as an indication of the total metabolic activity in each
well. Each condition was tested in quintuplicate.
FGFR/ligand binding assay
FGFR-binding activity of FGF19 and FGF19v were measured
as described in [25] using biotinylated anti-FGF19 antibody
(BAF969, R&D systems) in the presence of 2 mg/mL heparin.
Control ELISA experiments were performed using anti-FGF19
antibody (AF969, R&D systems) and biotinylated anti-FGF19
antibody (BAF969, R&D systems) to confirm that the antibody
reacts to FGF19 and FGF19v in an indistinguishable manner.
Mouse Studies
Mice were maintained in a pathogen-free animal facility at
21uC under standard 12 hr light/12 hr dark cycle with access to
chow (a standard rodent chow (Labdiet 5010, 12.7% calories from
fat) or a high fat, high carbohydrate diet (Harlan Teklad
TD.03584, 58.4% calories from fat) and water ad libitum. Male
mice were used for all of the experiments described. FGFR4 KO
mice in C57BL/6 background were previously described
[20,29,35]. C57BL/6 mice, ob/ob mice in C57BL/6 background
and FVB/NJ mice were purchased from Jackson Laboratory. For
continuous infusion of FGF protein, an osmotic pump (Alzet 2001)
was subcutaneously implanted. For glucose tolerance test, glucose
levels were measured using One Touch Ultra glucometer. BrdU
staining was carried out as described [15] and BrdU positive
hepatocytes were counted by using the Ariol automated image
analysis system.
Serum analysis
Total cholesterol, triglyceride, b-hydroxybutylate (BHB), lactate
(Thermo DMA) and nonesterified fatty acid (Roche) were
determined by using enzymatic reactions. Serum insulin levels
were determined by ELISA (Crystal Chem). BA composition was
determined by liquid chromatography-mass spectrometry analysis
as previously described [36].
Gene Expression Analysis
Tissue RNAs were isolated by using QIAzol reagent (Qiagen).
cDNA was synthesize with the Quantitect Reverse Transcription
Kit (Qiagen). For real time qPCR, samples were run in triplicate in
the ABI Prism 7900HT (Applied Biosystems) by using SYBR
green universal mix (Invitrogen) or by Taqman universal mix
(Roche) and normalized by levels of 36B4. Pre-designed
Quantitect primers for GK, SHP, Cyp8b1, IGFBP2, and AFP
were obtained from Qiagen and all other primers were designed
using primer express software (Applied Biosystems). Sequences of
in-house designed primers will be provided upon request.
Statistical Analyses
Unpaired student’s t-test (two-tailed) was used for statistical
analyses to compare treatment groups using Prism 5 software
(Graphpad) or Excel (Microsoft). A p-value ,0.05 was considered
statistically significant. Values were presented as means+/2
standard error of the mean.
Supporting Information
Figure S1 FGF21 and 19 activates FGFR2c and FGFR3c
in the presence of KLB. GAL-Elk1 luciferase assay in L6 cells.
L6 cells were cotransfected with expression vectors for KLB and
the indicated FGFR together with GAL-Elk1, SV40-Renilla
Luciferase, and Gal-responsive luciferase reporter. Transfected
cells were incubated with media containing increasing concentra-
tions of FGF19 (#) or FGF21(m) for 6 hours before luciferase
assays. Transcriptional activation was assessed by the relative
luciferase activity normalized by Renilla luciferase activity and
expressed as relative luciferase unit (RLU).
(TIF)
Figure S2 In vitro activity of FGF21, FGF19 and
chimeric constructs. GAL-Elk1 luciferase assay in rat L6 cells.
L6 cells were cotransfected with expression vectors for KLB and
the indicated FGFR together with GAL-Elk1, SV40-renilla
Luciferase, and Gal-responsive firefly luciferase reporter. Trans-
fected L6 cells were incubated for 6 hours before luciferase assays
with conditioned medium from 293 cells transiently transfected
with each FGF construct indicated at the bottom. The number
below each group corresponds to the number of the construct as
indicated in Fig. 2B. Transcriptional activation was assessed by the
relative firefly luciferase activity normalized by renilla luciferase
activity and expressed as relative luciferase unit (RLU). The results
Role of FGFR4 for FGF19 Activity
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mock transfected cells.
(TIF)
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